ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Cefoxitin: Drug information

Cefoxitin: Drug information
(For additional information see "Cefoxitin: Patient drug information" and see "Cefoxitin: Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Pharmacologic Category
  • Antibiotic, Cephalosporin (Second Generation)
Dosing: Adult

Usual dosage range: IV: 1 to 2 g every 6 to 8 hours.

Bite wound

Bite wound (animal) (off-label use): IV: 1 g every 6 to 8 hours (Ref).

Gonococcal infection, uncomplicated

Gonococcal infection, uncomplicated (infection of the cervix, rectum, or urethra) (alternative agent) (off-label use):

Note: Use cefoxitin only if ceftriaxone is unavailable given a lack of contemporary efficacy data (Ref).

IM: 2 g as a single dose plus oral probenecid; give in combination with treatment for chlamydia if it has not been excluded (Ref). When treatment failure is suspected (eg, detection of N. gonorrhoeae after treatment without additional sexual exposure), consult an infectious diseases specialist. Report failures to the CDC through state and local health departments (Ref).

Mycobacterial infection

Mycobacterial (nontuberculous, rapidly growing) infection (off-label use):

Patients without cystic fibrosis: 2 to 4 g two to three times daily or 200 mg/kg/day in 3 divided doses (maximum daily dosage: 12 g/day) as part of an appropriate combination regimen (Ref).

Patients with cystic fibrosis: 200 mg/kg/day in 3 divided doses (maximum daily dosage: 12 g/day) as part of an appropriate combination regimen (Ref).

Duration of therapy: The optimal duration of therapy is unknown, but generally the duration of parenteral therapy is ≤12 weeks depending on severity of infection, tolerability, and other patient-specific factors, followed by long-term oral maintenance therapy; consult an infectious diseases specialist for specific recommendations (Ref).

Pelvic inflammatory disease

Pelvic inflammatory disease:

Inpatients: IV: 2 g every 6 hours in combination with doxycycline. Total duration of therapy (which may include oral step-down therapy) is 14 days; oral therapy can usually be initiated within 24 to 48 hours of clinical improvement (Ref).

Outpatients: IM: 2 g as a single dose plus oral probenecid, followed by oral doxycycline and metronidazole for 14 days (Ref).

Surgical prophylaxis

Surgical (perioperative) prophylaxis: IV: 2 g within 60 minutes prior to surgical incision. Doses may be repeated in 2 hours if procedure is lengthy or if there is excessive blood loss (Ref).

Dosing: Kidney Impairment: Adult

The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.

Note: Single doses of IV or IM cefoxitin (eg, used for perioperative prophylaxis or outpatient treatment of pelvic inflammatory disease) do not require dosage adjustment for any degree of kidney dysfunction or in patients receiving kidney replacement therapies (Ref).

Altered kidney function:

Cefoxitin Dose Adjustments for Altered Kidney Function: IVa

CrCl

If the usual recommended dose is 1 to 2 g every 8 hours

If the usual recommended dose is 1 to 2 g every 6 hours

If the usual recommended dose is 200 mg/kg per day in 3 divided doses (maximum 12 g/day)b

a Humbert 1979; expert opinion; manufacturer's labeling.

b No data available. Recommendations based on expert opinion only.

CrCl >50 mL/minute

No dosage adjustment necessary

No dosage adjustment necessary

No dosage adjustment necessary

CrCl 30 to 50 mL/minute

1 to 2 g every 12 hours

1 to 2 g every 8 hours

150 mg/kg per day in 3 divided doses (maximum 9 g per day)

CrCl 10 to 29 mL/minute

1 to 2 g every 24 hours

1 to 2 g every 12 hours

100 mg/kg per day in 2 divided doses (maximum 6 g per day)

CrCl <10 mL/minute

1 g once, followed by 500 mg to 1 g every 24 hours

1 g every 24 hours

50 mg/kg per day in 1 or 2 divided doses (maximum 3 g per day)

Augmented renal clearance (measured urinary CrCl ≥130 mL/minute/1.73 m2):

Note: Augmented renal clearance (ARC) is a condition that occurs in certain critically ill patients without organ dysfunction and with normal serum creatinine concentrations. Younger patients (<55 years of age) admitted post trauma or major surgery are at highest risk for ARC, as well as those with sepsis, burns, or hematologic malignancies. An 8- to 24-hour measured urinary CrCl is necessary to identify these patients (Ref).

IV: Limited data for use of cefoxitin in ARC exist. For treatment of severe infections, consider alternative antimicrobial agents as the maximum daily dose (12 g per day) may still not achieve pharmacodynamic targets (Ref). If necessary, consider 2 g every 4 hours. Prolonged (continuous or extended) infusions may be necessary to optimize PK/PD target attainment (Ref).

Hemodialysis, intermittent (thrice weekly): Substantially dialyzable (exact % unknown) (Ref): IV: Dose as for CrCl <10 mL/minute. When scheduled dose falls on a hemodialysis day, administer after dialysis (Ref).

Peritoneal dialysis: Not significantly dialyzable: IV: Dose as for CrCl <10 mL/minute (Ref).

CRRT:

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) and minimal residual kidney function unless otherwise noted. Close monitoring of response and adverse reactions due to drug accumulation is important.

IV: Limited data exist for the use of cefoxitin in CRRT. Consider alternative antibiotic with more robust data for use. If necessary, dose as for CrCl 30 to 50 mL/minute.(Ref)

PIRRT (eg, sustained, low-efficiency diafiltration):

Note: Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Close monitoring of response and adverse reactions due to drug accumulation is important.

IV: Limited data exist for use of cefoxitin in PIRRT. Consider alternative antibiotic with more robust data for use.

If necessary:

PIRRT days: Dose as for CrCl 10 to 29 mL/minute, with one of the doses administered after the PIRRT session finishes (Ref).

Non-PIRRT days: Dose as for CrCl <10 mL/minute (Ref).

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric

(For additional information see "Cefoxitin: Pediatric drug information")

General dosing: Infants, Children, and Adolescents: Limited data available in infants <3 months of age: IM, IV: 80 to 160 mg/kg/day divided every 4 to 8 hours; maximum daily dose: 12 g/day (Ref).

Intra-abdominal infection

Intra-abdominal infection: Note: Cefoxitin is not recommended for the empiric treatment of intra-abdominal infection due to increasing resistance of anaerobic bacteria (ie, Bacteroides fragilis group); other options are preferred (Ref).

Infants, Children, and Adolescents: Limited data available in infants <3 months of age: IV: 80 to 160 mg/kg/day divided every 4 to 8 hours; maximum dose: 2,000 mg/dose. Use doses on the higher end of the range (ie, 160 mg/kg/day) for severe, complicated, or undrained infections (Ref). Treatment duration should be 4 to 7 days unless source control inadequate; in some circumstances (ie, acute or gangrenous appendicitis without perforation) therapy should be limited to ≤24 hours (Ref).

Mycobacterial infection, pulmonary infection in patients with or without cystic fibrosis

Mycobacterial (nontuberculous) infection (eg, Mycobacterium abscessus), pulmonary infection in patients with or without cystic fibrosis: Limited data available:

Infants, Children, and Adolescents: IV: 150 mg/kg/day divided every 6 to 8 hours; maximum daily dose: 12 g/day. The duration of parenteral therapy is generally 4 to 12 weeks depending on clinical response, followed by transition to oral and/or inhaled therapy; total antibiotic treatment duration is ≥12 months after culture conversion (Ref).

Pelvic inflammatory disease

Pelvic inflammatory disease:

Children ≥45 kg and Adolescents:

Mild to moderate (outpatient management): IM: 2,000 mg as a single dose, in combination with a single dose of probenecid, followed by 14 days of oral therapy with doxycycline and metronidazole (Ref).

Severe (inpatient management): IV: 2,000 mg every 6 hours in combination with doxycycline; once patient has clinically improved (typically within 24 to 48 hours), may transition to oral therapy with doxycycline and metronidazole to complete a total of 14 days of therapy (Ref).

Peritonitis, prophylaxis in patients undergoing GI or genitourinary procedures

Peritonitis (peritoneal dialysis), prophylaxis in patients undergoing GI or genitourinary procedures: Limited data available:

Infants, Children, and Adolescents: IV: 30 to 40 mg/kg administered 30 to 60 minutes before procedure; maximum dose: 2,000 mg/dose (Ref).

Surgical prophylaxis

Surgical prophylaxis:

Infants, Children, and Adolescents: Limited data available in infants <3 months of age: IV: 40 mg/kg within 60 minutes prior to surgery; may repeat dose in 2 hours for prolonged procedure or excessive blood loss; maximum dose: 2,000 mg/dose (Ref).

Dosing: Kidney Impairment: Pediatric

Infants, Children, and Adolescents: The manufacturer's labeling suggests dosing modification consistent with the adult recommendations. Some clinicians have used the following guidelines (Ref); Note: Renally adjusted dose recommendations are based on doses of 20 to 40 mg/kg/dose every 6 hours.

GFR >50 mL/minute/1.73 m2: No adjustment required.

GFR 30 to 50 mL/minute/1.73 m2: 20 to 40 mg/kg/dose every 8 hours.

GFR 10 to 29 mL/minute/1.73 m2: 20 to 40 mg/kg/dose every 12 hours.

GFR <10 mL/minute/1.73 m2: 20 to 40 mg/kg/dose every 24 hours.

Intermittent hemodialysis: Moderately dialyzable (20% to 50%): 20 to 40 mg/kg/dose every 24 hours.

Peritoneal dialysis (PD): 20 to 40 mg/kg/dose every 24 hours.

Continuous renal replacement therapy (CRRT): 20 to 40 mg/kg/dose every 8 hours.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%: Gastrointestinal: Diarrhea

<1%: Anaphylaxis, angioedema, bone marrow depression, dyspnea, eosinophilia, exacerbation of myasthenia gravis, exfoliative dermatitis, fever, hemolytic anemia, hypotension, increased blood urea nitrogen, increased serum creatinine, increased serum transaminases, interstitial nephritis, jaundice, leukopenia, nausea, nephrotoxicity (increased; with aminoglycosides), phlebitis, prolonged prothrombin time, pruritus, pseudomembranous colitis, skin rash, thrombocytopenia, thrombophlebitis, toxic epidermal necrolysis, urticaria, vomiting

Contraindications

Hypersensitivity to cefoxitin, any component of the formulation, or other cephalosporins

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated hypersensitivity reactions (eg, anaphylaxis, angioedema, urticaria). If a hypersensitivity reaction occurs, discontinue immediately.

• Superinfection: Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed >2 months postantibiotic treatment.

Disease-related concerns:

• GI disease: Use with caution in patients with a history of gastrointestinal disease, particularly colitis.

• Renal impairment: Use with caution in patients with renal impairment; modify dosage in severe impairment.

• Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.

Special populations:

• Children: In pediatric patients ≥3 months of age, higher doses have been associated with an increased incidence of eosinophilia and elevated AST.

• Older adult: This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Elderly patients are more likely to have decreased renal function; use care in dose selection and monitor renal function.

Other warnings/precautions:

• Discontinuation of therapy: For group A beta-hemolytic streptococcal infections, antimicrobial therapy should be given for at least 10 days to guard against the risk of rheumatic fever or glomerulonephritis.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Injection [preservative free]:

Generic: 10 g (1 ea)

Solution Reconstituted, Intravenous:

Generic: 2 g (1 ea)

Solution Reconstituted, Intravenous [preservative free]:

Generic: 1 g (1 ea); 2 g (1 ea)

Generic Equivalent Available: US

Yes

Pricing: US

Solution (reconstituted) (cefOXitin Sodium Intravenous)

1 g (per each): $3.60 - $11.94

2 g (per each): $7.20 - $23.94

10 g (per each): $60.00 - $112.25

Solution (reconstituted) (cefOXitin Sodium-Dextrose Intravenous)

1GM 4%(50ML) (per each): $22.63

2GM 2.2%(50ML) (per each): $40.25

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution Reconstituted, Injection:

Generic: 1 g (1 ea); 2 g (1 ea)

Solution Reconstituted, Intravenous:

Generic: 10 g (1 ea)

Administration: Adult

IM: Inject deep IM into large muscle mass. Note: IM injection is painful and this route of administration is not described in the prescribing information.

IV: Can be administered IVP over 3 to 5 minutes or by IV intermittent infusion over 10 to 60 minutes

Administration: Pediatric

Parenteral:

IV Push: Administer over 3 to 5 minutes.

Intermittent IV infusion: Administer over 15 to 60 minutes (Ref).

IM: Inject into a large muscle mass (Ref).

Use: Labeled Indications

Bacteremia/sepsis: Treatment of bacteremia/sepsis caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis.

Bone and joint infections: Treatment of bone and joint infections caused by S. aureus (including penicillinase-producing strains).

Gynecological infections: Treatment of endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by E. coli, Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including Bacteroides fragilis, Clostridium species, P. niger, Peptostreptococcus species, and Streptococcus agalactiae.

Limitations of use: Cefoxitin does not have activity against Chlamydia trachomatis. When cefoxitin is used to treat pelvic inflammatory disease, add appropriate antichlamydial coverage.

Lower respiratory tract infections: Treatment of pneumonia and lung abscess, caused by S. pneumoniae, other streptococci (excluding enterococci; eg, Enterococcus faecalis [formerly Streptococcus faecalis]), S. aureus (including penicillinase-producing strains), E. coli, Klebsiella species, Haemophilus influenzae, and Bacteroides species.

Septicemia: Treatment of septicemia caused by S. pneumoniae, S. aureus (including penicillinase-producing strains), E. coli, Klebsiella species, and Bacteroides species including B. fragilis.

Skin and skin structure infections: Treatment of skin and skin structure infections caused by S. aureus (including penicillinase-producing strains), Staphylococcus epidermidis, Streptococcus pyogenes and other streptococci (excluding enterococci [eg, E. faecalis] [formerly S. faecalis]), E. coli, Proteus mirabilis, Klebsiella species, Bacteroides species including B. fragilis, Clostridium species, P. niger, and Peptostreptococcus species.

Urinary tract infections: Treatment of UTIs caused by E. coli, Klebsiella species, P. mirabilis, Morganella morganii, Proteus vulgaris, and Providencia species (including Providencia rettgeri).

Use: Off-Label: Adult

Bite wounds (animal); Gonococcal infection, uncomplicated; Mycobacterial (nontuberculous, rapidly growing) infection

Medication Safety Issues
Sound-alike/look-alike issues:

CefOXitin may be confused with ceFAZolin, cefotaxime, cefoTEtan, cefTAZidime, cefTRIAXone, Cytoxan

Mefoxin may be confused with Lanoxin

Metabolism/Transport Effects

Substrate of OAT1/3

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Aminoglycosides: Cephalosporins may enhance the nephrotoxic effect of Aminoglycosides. Cephalosporins may decrease the serum concentration of Aminoglycosides. Risk C: Monitor therapy

Bacillus clausii: Antibiotics may diminish the therapeutic effect of Bacillus clausii. Management: Bacillus clausii should be taken in between antibiotic doses during concomitant therapy. Risk D: Consider therapy modification

BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). Risk X: Avoid combination

BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). Risk C: Monitor therapy

Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. Management: Avoid cholera vaccine in patients receiving systemic antibiotics, and within 14 days following the use of oral or parenteral antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Oral): May diminish the therapeutic effect of Antibiotics. Risk X: Avoid combination

Fecal Microbiota (Live) (Rectal): Antibiotics may diminish the therapeutic effect of Fecal Microbiota (Live) (Rectal). Risk X: Avoid combination

Furosemide: May enhance the nephrotoxic effect of Cephalosporins. Risk C: Monitor therapy

Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Antibiotics may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). Risk C: Monitor therapy

Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. Risk C: Monitor therapy

Probenecid: May increase the serum concentration of Cephalosporins. Risk C: Monitor therapy

Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate. Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic. Risk D: Consider therapy modification

Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected. Management: Avoid use of live attenuated typhoid vaccine (Ty21a) in patients being treated with systemic antibacterial agents. Postpone vaccination until 3 days after cessation of antibiotics and avoid starting antibiotics within 3 days of last vaccine dose. Risk D: Consider therapy modification

Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists. Risk C: Monitor therapy

Pregnancy Considerations

Cefoxitin crosses the placenta and reaches the cord serum and amniotic fluid.

An increased risk of major birth defects or other adverse fetal or maternal outcomes has generally not been observed following use of cephalosporin antibiotics, including cefoxitin, during pregnancy.

Cefoxitin is one of the antibiotics recommended for prophylactic use prior to cesarean delivery (ACOG 199 2018).

Breastfeeding Considerations

Cefoxitin is present in breast milk.

The estimated dose to a breastfed infant would be <0.1% of the maternal dose. According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother. However, cephalosporins are generally considered acceptable for use in breastfeeding women (Ito 2000). In general, antibiotics that are present in breast milk may cause nondose-related modification of bowel flora. Monitor infants for GI disturbances, such as thrush or diarrhea (WHO 2002).

Dietary Considerations

Some products may contain sodium.

Monitoring Parameters

Monitor renal function periodically when used in combination with other nephrotoxic drugs; prothrombin time. Observe for signs and symptoms of anaphylaxis during first dose. CBC with prolonged use (ATS/ERS/ESCMID/IDSA [Daley 2020]).

Mechanism of Action

Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.

Pharmacokinetics (Adult Data Unless Noted)

Distribution: Widely to body tissues and fluids including ascitic, pleural, synovial, bile; poorly penetrates into CSF even with inflammation of the meninges (Landesman 1981).

Vd:

Neonates and Infants <2 months of age (PNA: 10 to 53 days): 0.5 ± 0.21 L/kg (Regazzi 1983).

Protein binding: 65% to 79%.

Half-life elimination:

Neonates and Infants <2 months of age (PNA: 10 to 53 days): 1.4 hours (Regazzi 1983).

Infants ≥3 months of age and Children: 42.4 ± 5.3 minutes (Feldman 1980).

Adults: 41 to 59 minutes; prolonged with renal impairment.

Time to peak, serum: IM: Within 20 to 30 minutes.

Excretion: Urine (85% as unchanged drug).

Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)

Anti-infective considerations:

Parameters associated with efficacy:

Time dependent; associated with time free drug concentration (fT) > minimum inhibitory concentration (MIC): Goal: ≥40% to 50% (fT) > MIC (bacteriostatic), ≥60% to 70% (fT) > MIC (bactericidal) (Abdul-Aziz 2020; Craig 1996; Craig 1998; Turnidge 1998).

Expected drug exposure in normal renal function:

Pediatric patients: Cmax (peak):

Single dose (30 mg/kg): IV: Neonates and Infants <2 months of age (PNA: 10 to 53 days): 69.8 ± 31.9 mg/L (Regazzi 1983).

Steady state (37.5 mg/kg/dose every 6 hours): IV: Infants ≥3 months and Children: 81.9 ± 33 mg/L (Feldman 1980).

Adults: Cmax (peak): Single dose (2 g): IV: 118.9 to 158.6 mg/L (Carver 1989; Isla 2012).

Postantibiotic effect: Generally <1 hour; varies by organism (Craig 1991; Craig 1998). For Bacteroides spp.: Variable, ranging from 0 to 15 hours (Aldridge 2002; Siverhus 1988).

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AE) United Arab Emirates: Foxitin | Mefoxin;
  • (AR) Argentina: Cefoxitima richet | Cefoxitina fabra | Cefoxona | Mefoxin;
  • (AT) Austria: Cefoxitin | Mefoxitin;
  • (AU) Australia: Cefoxitin | Mefoxin;
  • (BE) Belgium: Mefoxin;
  • (BG) Bulgaria: Mefoxin;
  • (BR) Brazil: Cefoxit | Cefoxitina sodica | Cefton | Foxtil | Kefox | Mefoxin | Propoten;
  • (CN) China: Cefoxitin | Da li ding | Fa ke | Fa li ke | Mefoxin | Pai qi xin | Pai qin | Wei Bo Xin | Yi fu xin | Yue le xin;
  • (CO) Colombia: Cefoxin | Mefoxitin;
  • (CZ) Czech Republic: Mefoxin;
  • (DO) Dominican Republic: Mefoxin;
  • (EE) Estonia: Cefoxitina | Cefoxitina ldp laboratorios torlan | Cefoxitina normon | Mefoxin | Mefoxitin;
  • (EG) Egypt: Plucefox;
  • (ES) Spain: Cefaxicina | Cefoxitina Ips | Cefoxitina ldp laboratorios torlan | Cefoxitina normon | Mefoxitin;
  • (FI) Finland: Mefoxin;
  • (FR) France: Cefoxitine hospira | Cefoxitine panpharma | Mefoxin;
  • (GB) United Kingdom: Mefoxin | Renoxitin;
  • (GR) Greece: Destrepen | Mefoxil;
  • (HK) Hong Kong: Mefoxin;
  • (HU) Hungary: Mefoxin;
  • (IT) Italy: Mefoxin;
  • (JO) Jordan: Foxitin | Mefoxin | Voxitin;
  • (JP) Japan: Cenomycin | Merxin banyu | Merxin torii | Taimetacin;
  • (KR) Korea, Republic of: Cefoxitin | Cetazin | Jeitin | Pacetin | Shinpoong cefoxitin sodium | Union cefoxitin | Yooyoung cefoxitine sodium;
  • (LB) Lebanon: Mefoxin;
  • (LT) Lithuania: Mefoxin;
  • (LV) Latvia: Mefoxin | Tarcefoxin;
  • (NL) Netherlands: Mefoxin;
  • (NO) Norway: Mefoxitin;
  • (NZ) New Zealand: Cefoxitin actavis;
  • (PE) Peru: Mefoxin;
  • (PH) Philippines: Acifox | Alfoxin | Cefovex | Cefoxivit | Dintaxin | Foxitin | Geoxin | Haxotin | Mefoxin | Monowel | Onexitine | Oximed | Pacetin | Panafox | Xifox | Xitin | Zengram | Zepax;
  • (PL) Poland: Mefoxin | Mefoxitin;
  • (PR) Puerto Rico: Cefoxitin | Mefoxin;
  • (PT) Portugal: Atralxitina | Cefoxitina | Cefoxitina basi | Cefoxitina hikma | Mefoxin;
  • (RU) Russian Federation: Ambicef | Anaerocef | Cefoxitin | Mefoxin;
  • (SA) Saudi Arabia: Foxitin | Mefoxin;
  • (SK) Slovakia: Mefoxin;
  • (TH) Thailand: Cefoxin | Cefxitin | Maxotin;
  • (TR) Turkey: Mefoxin;
  • (TW) Taiwan: Cefmore | Cefoxitin | Cexitin | Kinfotin | Lefoxin | Lephocin | Lifoxitin | Lofatin | Mefoxin;
  • (UA) Ukraine: Mefoxin;
  • (VE) Venezuela, Bolivarian Republic of: Mefoxitin;
  • (VN) Viet Nam: Tenafotin 2000;
  • (ZA) South Africa: Mefoxin | Pharmacare-cefoxitin | Sabax cefoxitin
  1. Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al; Infection Section of European Society of Intensive Care Medicine (ESICM); Pharmacokinetic/pharmacodynamic and critically ill patient study groups of European Society of Clinical Microbiology and Infectious Diseases (ESCMID); Infectious Diseases Group of International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT); Infections in the ICU and Sepsis Working Group of International Society of Antimicrobial Chemotherapy (ISAC). Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46(6):1127-1153. doi:10.1007/s00134-020-06050-1 [PubMed 32383061]
  2. Abramowicz M, “Antimicrobial Prophylaxis in Surgery,” Medical Letter on Drugs and Therapeutics, Handbook of Antimicrobial Therapy, 16th ed, New York, NY: Medical Letter, 2002.
  3. Aldridge KE. Comparison of the post-antibiotic effect (PAE) induced by ceftizoxime, ceftriaxone, cefoxitin, ampicillin-sulbactam, and ticarcillin-clavulanate against selected isolates of Bacteroides fragilis and B. thetaiotaomicron. Anaerobe. 2002;8(6):295-299. doi:10.1016/S1075-9964(03)00024-6 [PubMed 16887672]
  4. American Academy of Pediatrics (AAP). In: Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH, eds. Red Book: 2021-2024 Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021.
  5. American College of Obstetricians and Gynecologists (ACOG), Committee on Practice Bulletins-Obstetrics. ACOG practice bulletin no. 199: Use of prophylactic antibiotics in labor and delivery [published correction appears in Obstet Gynecol. 2019;134(4):883-884]. Obstet Gynecol. 2018;132(3):e103‐e119. doi:10.1097/AOG.0000000000002833 [PubMed 30134425]
  6. Aronoff GR, Bennett WM, Berns JS, et al. Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children, 5th ed. Philadelphia, PA: American College of Physicians; 2007.
  7. Arvidsson A, Alván G, Tranaeus A, Malmborg AS. Pharmacokinetic studies of cefoxitin in continuous ambulatory peritoneal dialysis. Eur J Clin Pharmacol. 1985;28(3):333-337. doi:10.1007/BF00543333 [PubMed 4007038]
  8. Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, Isla A, Solinís MÁ. Augmented renal clearance in critically ill patients: a systematic review. Clin Pharmacokinet. 2018;57(9):1107-1121. doi:10.1007/s40262-018-0636-7 [PubMed 29441476]
  9. Bratzler DW, Dellinger EP, Olsen KM, et al, “Clinical Practice Guidelines for Antimicrobial Prophylaxis in Surgery,” Am J Health Syst Pharm, 2013, 70(3):195-283. [PubMed 23327981]
  10. “Antimicrobial Prophylaxis in Surgery,” Med Lett Drugs Ther, 1993, 35(906):91-4. [PubMed 8371696]
  11. Bratzler DW, Houck PM, Surgical Infection Prevention Guidelines Writers Workgroup, et al, “Antimicrobial Prophylaxis for Surgery: An Advisory Statement From the National Surgical Infection Prevention Project,” Clin Infect Dis, 2004, 38(12):1706-15. [PubMed 15227616]
  12. Buchanan N, Mithal Y, Witcomb M. Cefoxitin: intravenous pharmacokinetics and intramuscular bioavailability in kwashiorkor. Br J Clin Pharmacol. 1980;9(6):623-627. doi:10.1111/j.1365-2125.1980.tb01093.x [PubMed 7387820]
  13. Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989;23(1):99-106. doi:10.1093/jac/23.1.99 [PubMed 2745258]
  14. Cefoxitin injection, USP [prescribing information]. Lake Zurich, IL: Fresenius Kabi; May 2021.
  15. Cefoxitin injection [prescribing information]. Schaumburg, IL: Sagent Pharmaceuticals; September 2018.
  16. Cefoxitin injection pharmacy bulk package [prescribing information]. Eatontown, NJ: West-Ward; May 2018.
  17. Chabert P, Provoost J, Cohen S, et al. Pharmacokinetics, efficacy and tolerance of cefoxitin in the treatment of cefoxitin-susceptible extended-spectrum beta-lactamase producing Enterobacterales infections in critically ill patients: a retrospective single-center study. Ann Intensive Care. 2022;12(1):90. doi:10.1186/s13613-022-01059-9 [PubMed 36175707]
  18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26(1):1-10; quiz 11-12. doi:10.1086/516284 [PubMed 9455502]
  19. Craig WA. The postantibiotic effect. Clin Microbiology Newsletter. 1991;13(16):121-124. doi:10.1016/0196-4399(91)90030-Y
  20. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255-259. doi:10.1097/00006454-199603000-00015 [PubMed 8852915]
  21. Daley CL, Iaccarino JM, Lange C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin Infect Dis. 2020;71(4):905-913. doi:10.1093/cid/ciaa1125 [PubMed 32797222]
  22. Donowitz GR and Mandell GL, “Beta-Lactam Antibiotics,” N Engl J Med, 1988, 318(7):419-26 and 318(8):490-500. [PubMed 3277054]
  23. Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.
  24. Farmer K. Use of cefoxitin in the newborn. N Z Med J. 1982;95(709):398. [PubMed 6955661]
  25. Feldman WE, Moffitt S, Sprow N. Clinical and pharmacokinetic evaluation of parental cefoxitin in infants and children. Antimicrob Agents Chemother. 1980;17(4):669-674. doi:10.1128/AAC.17.4.669 [PubMed 7396456]
  26. Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary. Thorax. 2016;71(1):88-90. [PubMed 26678435]
  27. Garcia MJ, Dominguez-Gil A, Tabernero JM, Bondia Román A. Pharmacokinetics of cefoxitin in patients undergoing hemodialysis. Int J Clin Pharmacol Biopharm. 1979;17(8):366-370. [PubMed 489205]
  28. Garcia MJ, Garcia A, Nieto MJ, et al, “Disposition of Cefoxitin in the Elderly,” Int J Clin Pharmacol Ther Toxicol, 1980, 18(11):503-9. [PubMed 7203727]
  29. Garrelts JC, Ast D, LaRocca J, Smith DF Jr, Peterie JD. Postinfusion phlebitis after intravenous push versus intravenous piggyback administration of antimicrobial agents. Clin Pharm. 1988;7(10):760-765. [PubMed 3233896]
  30. Goutelle S, Jullien V, Bru JP, et al. Defining standard and high dosages for β-lactam agents administered by intermittent, prolonged or continuous infusion: a PK/PD simulation study. J Antimicrob Chemother. 2023;78(11):2762-2769. doi:10.1093/jac/dkad300 [PubMed 37796958]
  31. Greaves WL, Kreeft JH, Ogilvie RI, Richards GK. Cefoxitin disposition during peritoneal dialysis. Antimicrob Agents Chemother. 1981;19(2):253-255. doi:10.1128/AAC.19.2.253 [PubMed 7347560]
  32. Gutiérrez C, Vila J, Garcia-Sala C, et al. Study of appendicitis in children treated with four different antibiotic regimens. J Pediatr Surg. 1987;22(9):865-868. doi:10.1016/s0022-3468(87)80657-7 [PubMed 3312564]
  33. Haworth CS, Banks J, Capstick T, et al. British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax. 2017;72(suppl 2):ii1-ii64. doi:10.1136/thoraxjnl-2017-210927 [PubMed 29054853]
  34. Humbert G, Fillastre JP, Leroy A, Godin M, Van Winzum C. Pharmacokinetics of cefoxitin in normal subjects and in patients with renal insufficiency. Rev Infect Dis. 1979;1(1):118-126. doi:10.1093/clinids/1.1.118 [PubMed 318213]
  35. Isla A, Trocóniz IF, de Tejada IL, et al. Population pharmacokinetics of prophylactic cefoxitin in patients undergoing colorectal surgery. Eur J Clin Pharmacol. 2012;68(5):735-745. doi:10.1007/s00228-011-1206-1 [PubMed 22246211]
  36. Ito S. Drug therapy for breast-feeding women [published correction appears in N Engl J Med. 2000;343(18):1348]. N Engl J Med. 2000;343(2):118‐126. doi:10.1056/NEJM200007133430208 [PubMed 10891521]
  37. Jacobson JA, Santos JI, Palmer WM. Clinical and bacteriological evaluation of cefoxitin therapy in children. Antimicrob Agents Chemother. 1979;16(2):183-185. doi:10.1128/AAC.16.2.183 [PubMed 485129]
  38. Landesman SH, Corrado ML, Shah PM, Armengaud M, Barza M, Cherubin CE. Past and current roles for cephalosporin antibiotics in treatment of meningitis. Emphasis on use in gram-negative bacillary meningitis. Am J Med. 1981;71(4):693-703. [PubMed 6269429]
  39. Lipsky BA, Berendt AR, Cornia PB, et al, "2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infections," Clin Infect Dis, 2012, 54(12):e132-73. [PubMed 22619242]
  40. Marshall WF and Blair JE, “The Cephalosporins,” Mayo Clin Proc, 1999, 74(2):187-95. [PubMed 10069359]
  41. McCloskey RV. Intramuscular cefoxitin. Rev Infect Dis. 1979;1(1):224-227. [PubMed 400934]
  42. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt). 2017;18(1):1-76. [PubMed 28085573]
  43. Mefoxin (cefoxitin) [prescribing information]. Rockford, IL: Mylan Institutional LLC; February 2017.
  44. Refer to manufacturer's labeling.
  45. Regazzi MB, Chirico G, Cristiani D, Rondini G, Rondanelli R. Cefoxitin in newborn infants. A clinical and pharmacokinetic study. Eur J Clin Pharmacol. 1983;25(4):507-509. doi:10.1007/BF00542119 [PubMed 6653646]
  46. Robinson DC, Cookson TL, Grisafe JA. Concentration guidelines for parenteral antibiotics in fluid-restricted patients. Drug Intell Clin Pharm. 1987;21(12):985-989. doi:10.1177/106002808702101212 [PubMed 3428165]
  47. Roos R, von Hattingberg HM, Belohradsky BH, et al. Pharmacokinetics of cefoxitin in premature and newborn infants studied by continuous serum level monitoring during combination therapy with penicillin and amikacin. Infection. 1980;8(6):301-306.
  48. Rosaschino F, Vita CR, Bosco U, Castelli F, Vercelloni M. Clinical study with cefoxitin in paediatrics. Drugs Exp Clin Res. 1985;11(3):195-199. [PubMed 3915286]
  49. Santos JI, Jacobson JA, Swensen P, Palmer WM. Cellulitis: treatment with cefoxitin compared with multiple antibiotic therapy. Pediatrics. 1981;67(6):887-890. [PubMed 7015265]
  50. Siverhus DJ, Edmiston CE Jr, Clausz JC, Goheen MP. Post-antibiotic effect in Bacteroides fragilis group. Ann Clin Lab Sci. 1988;18(4):326-336. [PubMed 3165611]
  51. Solomkin JS, Mazuski JE, Bradley JS, et al, “Diagnosis and Management of Complicated Intra-Abdominal Infections in Adults and Children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America,” Clin Infect Dis, 2010, 50(2):133-64. [PubMed 20034345]
  52. Sonneville PF, Albert KS, Skeggs H, Gentner H, Kwan KC, Martin CM. Effect of lidocaine on the absorption, disposition and tolerance of intramuscularly administered cefoxitin. Eur J Clin Pharmacol. 1977;12(4):273-279. [PubMed 590313]
  53. Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America [published online June 18, 2014]. Clin Infect Dis. 2014;59(2):e10-52. doi: 10.1093/cid/ciu296. [PubMed 24947530]
  54. Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections. Clin Infect Dis. Published online July 18, 2023. doi:10.1093/cid/ciad428 [PubMed 37463564]
  55. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10-22. doi:10.1086/514622 [PubMed 9675443]
  56. Vlasses PH, D'Silva H, Rocci ML Jr, et al. Disposition of intravenous and intraperitoneal cefoxitin during chronic intermittent peritoneal dialysis. Am J Kidney Dis. 1983;3(1):67-70. doi:10.1016/s0272-6386(83)80013-4 [PubMed 6869373]
  57. Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet. 2010;49(1):1-16. doi:10.2165/11318140-000000000-00000 [PubMed 20000886]
  58. Warady BA, Bakkaloglu S, Newland J, et al. Consensus guidelines for the prevention and treatment of catheter-related infections and peritonitis in pediatric patients receiving peritoneal dialysis: 2012 update. Perit Dial Int. 2012;(32 Suppl 2):S32-S86. [PubMed 22851742]
  59. Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1 [PubMed 34292926]
  60. World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/
Topic 9223 Version 269.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟